HRP20220151T1 - Višenamjenski sastav torasemida - Google Patents
Višenamjenski sastav torasemida Download PDFInfo
- Publication number
- HRP20220151T1 HRP20220151T1 HRP20220151TT HRP20220151T HRP20220151T1 HR P20220151 T1 HRP20220151 T1 HR P20220151T1 HR P20220151T T HRP20220151T T HR P20220151TT HR P20220151 T HRP20220151 T HR P20220151T HR P20220151 T1 HRP20220151 T1 HR P20220151T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- preparation according
- weight
- propane
- torasemide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 12
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title claims 6
- 229960005461 torasemide Drugs 0.000 title claims 6
- 238000002360 preparation method Methods 0.000 claims 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 6
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 6
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 6
- 238000002156 mixing Methods 0.000 claims 5
- 239000003960 organic solvent Substances 0.000 claims 5
- 230000003113 alkalizing effect Effects 0.000 claims 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 150000001298 alcohols Chemical class 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 239000001294 propane Substances 0.000 claims 3
- 239000006254 rheological additive Substances 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 239000012298 atmosphere Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229920001971 elastomer Polymers 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 239000005060 rubber Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 229960000281 trometamol Drugs 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1851353A FR3077984B1 (fr) | 2018-02-16 | 2018-02-16 | Composition multiusage de torasemide |
| EP19710750.1A EP3752129B1 (fr) | 2018-02-16 | 2019-02-15 | Composition multiusage de torasemide |
| PCT/FR2019/050345 WO2019158873A1 (fr) | 2018-02-16 | 2019-02-15 | Composition multiusage de torasemide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220151T1 true HRP20220151T1 (hr) | 2022-04-15 |
Family
ID=62167516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220151TT HRP20220151T1 (hr) | 2018-02-16 | 2019-02-15 | Višenamjenski sastav torasemida |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11337921B2 (pt) |
| EP (1) | EP3752129B1 (pt) |
| JP (1) | JP7254101B2 (pt) |
| KR (1) | KR20200121835A (pt) |
| CN (1) | CN111741745B (pt) |
| AU (1) | AU2019221126B2 (pt) |
| BR (1) | BR112020016597B1 (pt) |
| CA (1) | CA3090570A1 (pt) |
| DK (1) | DK3752129T3 (pt) |
| ES (1) | ES2907143T3 (pt) |
| FR (1) | FR3077984B1 (pt) |
| HR (1) | HRP20220151T1 (pt) |
| HU (1) | HUE057602T2 (pt) |
| PL (1) | PL3752129T3 (pt) |
| PT (1) | PT3752129T (pt) |
| RU (1) | RU2020130402A (pt) |
| SI (1) | SI3752129T1 (pt) |
| WO (1) | WO2019158873A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3906020A1 (en) * | 2019-01-04 | 2021-11-10 | SQ Innovation AG | Pharmaceutical compositions of torsemide and uses thereof |
| CN114376969A (zh) * | 2020-10-19 | 2022-04-22 | 南京济群医药科技股份有限公司 | 一种托拉塞米注射液及其制备方法 |
| CN112168776B (zh) * | 2020-10-30 | 2022-05-03 | 康普药业股份有限公司 | 一种低杂质高稳定的托拉塞米注射液和制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3623620A1 (de) * | 1986-07-12 | 1988-01-21 | Boehringer Mannheim Gmbh | Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung |
| DE10013289A1 (de) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Torasemid enthaltende pharmazeutische Zubereitungen |
| EP1895983A2 (en) * | 2005-05-27 | 2008-03-12 | Panacea Biotec Ltd. | Injectable compositions and process for preparation of such compositions |
| CN101007003A (zh) * | 2007-02-01 | 2007-08-01 | 扬子江药业集团南京海陵药业有限公司 | 一种稳定的托拉塞米注射液及其制备方法 |
| CN102512360B (zh) * | 2011-12-09 | 2014-06-25 | 天津市汉康医药生物技术有限公司 | 稳定安全的供注射用托拉塞米药物组合物 |
| BR112014028602B1 (pt) * | 2012-05-18 | 2023-10-24 | Luoda Pharma Limited | Formulação líquida não aquosa oralmente biodisponível para administração oral |
| MX2017015670A (es) * | 2015-06-08 | 2018-08-15 | Dermarc LLC | Composicion terapeutica. |
-
2018
- 2018-02-16 FR FR1851353A patent/FR3077984B1/fr active Active
-
2019
- 2019-02-15 WO PCT/FR2019/050345 patent/WO2019158873A1/fr unknown
- 2019-02-15 US US16/969,848 patent/US11337921B2/en active Active
- 2019-02-15 ES ES19710750T patent/ES2907143T3/es active Active
- 2019-02-15 CA CA3090570A patent/CA3090570A1/fr active Pending
- 2019-02-15 CN CN201980013677.XA patent/CN111741745B/zh active Active
- 2019-02-15 AU AU2019221126A patent/AU2019221126B2/en active Active
- 2019-02-15 HR HRP20220151TT patent/HRP20220151T1/hr unknown
- 2019-02-15 EP EP19710750.1A patent/EP3752129B1/fr active Active
- 2019-02-15 BR BR112020016597-2A patent/BR112020016597B1/pt active IP Right Grant
- 2019-02-15 JP JP2020566330A patent/JP7254101B2/ja active Active
- 2019-02-15 SI SI201930166T patent/SI3752129T1/sl unknown
- 2019-02-15 DK DK19710750.1T patent/DK3752129T3/da active
- 2019-02-15 HU HUE19710750A patent/HUE057602T2/hu unknown
- 2019-02-15 RU RU2020130402A patent/RU2020130402A/ru unknown
- 2019-02-15 PT PT197107501T patent/PT3752129T/pt unknown
- 2019-02-15 KR KR1020207026462A patent/KR20200121835A/ko not_active Application Discontinuation
- 2019-02-15 PL PL19710750T patent/PL3752129T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7254101B2 (ja) | 2023-04-07 |
| EP3752129A1 (fr) | 2020-12-23 |
| FR3077984A1 (fr) | 2019-08-23 |
| HUE057602T2 (hu) | 2022-06-28 |
| WO2019158873A1 (fr) | 2019-08-22 |
| EP3752129B1 (fr) | 2021-11-24 |
| JP2021514393A (ja) | 2021-06-10 |
| PT3752129T (pt) | 2022-02-03 |
| AU2019221126B2 (en) | 2024-06-13 |
| BR112020016597A2 (pt) | 2020-12-15 |
| CN111741745A (zh) | 2020-10-02 |
| FR3077984B1 (fr) | 2020-02-21 |
| CN111741745B (zh) | 2024-03-26 |
| BR112020016597B1 (pt) | 2022-11-16 |
| RU2020130402A (ru) | 2022-03-16 |
| KR20200121835A (ko) | 2020-10-26 |
| US20200375898A1 (en) | 2020-12-03 |
| ES2907143T3 (es) | 2022-04-22 |
| AU2019221126A1 (en) | 2020-08-27 |
| US11337921B2 (en) | 2022-05-24 |
| DK3752129T3 (da) | 2022-02-21 |
| PL3752129T3 (pl) | 2022-03-21 |
| SI3752129T1 (sl) | 2022-04-29 |
| CA3090570A1 (fr) | 2019-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220151T1 (hr) | Višenamjenski sastav torasemida | |
| ES2508290T3 (es) | Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo | |
| CR20210201A (es) | Nuevos compuestos antihelmínticos | |
| AR110270A1 (es) | Preparación de complejos sólidos de ciclodextrina para la administración de ingredientes farmacéuticos activos oftálmicos | |
| JP2016027060A5 (pt) | ||
| PH12016501357A1 (en) | Pharmaceutical preparation containing pyridylamino acetic acid compound | |
| AR080242A1 (es) | Composiciones veterinarias. usos. | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| WO2018160178A8 (en) | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof | |
| BR112015027024A2 (pt) | formulações de gel para liberação prolongada de compostos voláteis | |
| JP5217136B2 (ja) | 直腸、尿道および膣適用用半固形状製剤。 | |
| CO2020006789A2 (es) | Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico | |
| MX2023007036A (es) | Formulaciones de liberacion prolongada para aplicaciones intra-articulares. | |
| MX2023006235A (es) | Composiciones para administracion de farmacos y metodos de uso de las mismas. | |
| JP2017523149A5 (pt) | ||
| ES2719815T3 (es) | Composición farmacéutica oral de mesilato de imatinib y proceso para la preparación de la misma | |
| ZA202301927B (en) | Phytonadione compositions | |
| AR063111A1 (es) | Una formulacion farmaceutica de taxano | |
| US20180264118A1 (en) | Hydrogel formulation with mild adhesion | |
| RU2017144216A (ru) | Антибактериальные композиции | |
| WO2016184577A3 (en) | Dry powder composition comprising long-chain rna | |
| WO2016123482A3 (en) | Sustained-release oral dosage forms for low aqueous solubility compounds | |
| EP3494970A3 (en) | Hardly soluble therapeutic agents belonging to bcs class ii or iv suspended in the liquid formulation and/or in the final nanofibrous structure | |
| PE20131339A1 (es) | Formulaciones para el factor estimulante de colonias de granulocitos bovino y variantes de las mismas | |
| AR103466A1 (es) | Formulación galenica que comprende un fármaco tópico |